views

Directa Plus – argues recent “strong performance”, but how strong really?

Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced that it “now expects revenues for FY22 to be not less than €10.8m, as a result of a strong performance in December, which represents a c.25% increase on the prior year” and that there is current “robust growth across all verticals supported by a strengthening pipeline of potential opportunities”. So what of a share price presently up to 86p?

views

Directa Plus – trading warning. How much faith to have in its stated 2023 confidence?

Previously writing on company describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA), in October with the shares up to 89.5p I concluded that its recent announcements and above £59 million market cap meant that I retained caution, still avoid/sell. The shares last closed at 83.8p but are currently falling well below 80p on the back of a “trading update”.

NEWSFLOW

Directa Plus (#DCTA) – trading delays, argues due to ‘supply chain, macro and geopolitical factors’

views

Directa Plus – “first commercial contract in Latin America”, again ramptastic?

Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) emphasises a “first commercial contract in Latin America” and the shares have currently responded up to 89.5p.

views

Directa Plus – ‘first major commercial contract for Gipave’, “a significant validation”?

Directa Plus (DCTA) has announced “a significant validation of our product… asphalt for the A4 Torino-Milano motorway section, managed by the ASTM Group will be made with G+ graphene”. So what of a current share price of 87.5p, up more than 14% on this news?

views

Directa Plus – interims, is this really ‘a leading producer and supplier maintaining a positive outlook’?

Writing on company which describes itself as “a leading producer and supplier of graphene-based products for use in consumer and industrial markets” Directa Plus (DCTA) at the start of this month with the shares just below 90p I concluded, ahead of the half-year financial detail, still avoid / sell. So what of the now-announced results and the shares more than 12% lower at 76.5p?

views

Directa Plus – argues “continues to perform strongly”. Does it?

Writing on company which describes itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) earlier this week, I noted US patents development and “generating considerable interest”, but what about the financials?. So what of now a “pleased to provide… trading update ahead of the announcement of its half year results for the six months to 30 June 2022 on 29 September”?

views

Directa Plus – US patents development and “generating considerable interest”, but what about the financials?

Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced it “has received a Notice of Allowance from the United States Patent and Trademark Office for the grant of a patent covering the Company's G+ embedded polyurethane membrane”, with the offering “generating considerable interest in the US market”. So what of a current 90p share price?

NEWSFLOW

Directa Plus (#DCTA) – revenue “acceleration”, but what about the bottom-line?

views

Directa Plus – 2021 results, how “comfortable” with forecasts?...

Producer and supplier of graphene nanoplatelets-based products Directa Plus (DCTA) has announced 2021 results emphasising “revenue and profitability which have exceeded consensus market expectations” and “a number of exciting opportunities in our targeted markets”. So what of a current 121.5p share price?...